tbuckley/cabot-search huggingface dataset:
Update Alert 8: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Authors: Katherine Mackey, Devan Kansagara, Kathryn Vela
Journal: Annals of Internal Medicine (2021)

searched MEDLINE (Ovid) weekly from 1 September to 28 September 2020 using the same search strategy as described in the original review (1).We did not limit the search by language.This search update yielded 77 results (de-duplicated), and after an independent dual-review process, we identified 15 new studies meeting our inclusion criteria-8 observational studies, 6 systematic reviews with meta-analyses, and 1 clinical trial protocol.New Evidence Findings from 2 observational studies, 1 of which is an update of a previously published retrospective analysis of insurance data in South Korea, found no evidence of an association between angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) use and risk for coronavirus disease 2019 (COVID-19) (2, 3).This South Korean study and an additional 6 observational studies found no association between the use of ACEIs or ARBs and COVID-19 disease severity (3-9).These studies include a retrospective analysis of the association of ACEI or ARB use on need for mechanical ventilation and mortality among a predominantly Hispanic/Latino and African American population in New York City treated for COVID-19 in March 2020, which, like prior studies, found no difference (4).These findings are supported by 6 new systematic reviews with meta-analyses, except for 1 review finding a mildly increased risk for infection among patients younger than 60 years using ARBs (adjusted odds ratio, 1.09 [95% CI, 1.01 to 1.18]) (10 -15).Overall, inclusion of 15 studies from this search update does not change the certainty of evidence rating we reported in the original manuscript for key questions 1 or 2. Studies have not examined the benefits and harms of initiating ACEIs or ARBs (that is, new users) in COVID-19 treatment; therefore, evidence for key question 3 remains unclear.In-Progress TrialWe identified 1 new in-progress trial evaluating hospitalrelated outcomes among adults admitted with COVID-19 who either continued or discontinued ACEIs or ARBs (16).
THE DEADLY PNEUMOCOCCUS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
Authors: Lauren Christine Harshman, Maneka Puligandla, Naomi B. Haas, Charles G. Drake, David F. McDermott, Sabina Signoretti, David Cella, Rajan T Gupta, Lynne I. Wagner, Brian M. Shuch, Primo Lara, Toni K. Choueiri, Anil Kapoor, Daniel Yick Chin Heng, M. Dror Michaelson, Michael A.S. Jewett, Eliezer Mendel Van Allen, Daniel J. George, Michael Anthony Carducci, Mohamad Allaf
Journal: Journal of Clinical Oncology (2018)

TPS4597 Background: As of 2018, there is no standard adjuvant systemic therapy that increases overall survival (OS) over surgery alone for patients with non-metastatic RCC. Nivolumab (nivo), an antibody against PD-1, improves overall survival in metastatic RCC and is well tolerated. Mouse solid tumor models have revealed an OS benefit to a short course of PD-1 blockade when given neoadjuvantly compared to adjuvantly. Two ongoing phase 2 studies of perioperative nivo in M0 RCC patients are showing preliminary feasibility and safety with no surgical delays (NCT02575222; NCT02595918). The PROSPER RCC trial will examine if administering perioperative nivo with radical or partial nephrectomy can increase cures, time to recurrence and survival in patients with high risk localized and locally advanced RCC. Methods: This global, unlinded, phase 3 National Clinical Trials Network study is accruing patients with clinical stage ≥T2 or node positive M0 RCC of any histology. Tumor biopsy prior to randomization is mandatory to ensure RCC and will also permit unparalleled correlative science. The investigational arm will receive two doses of nivo prior to surgery followed by adjuvant nivo for 9 months (q2 wks x 3 mo followed by q4 wks x 6 mo). The control arm will receive standard of care surgical resection followed by observation. Randomization will be stratified by clinical T stage, node positivity, and histology. With 766 patients, there is 84.2% power to detect a 14% absolute benefit in recurrence-free survival (RFS) at 5 years assuming the ASSURE historical control of ~56% to 70% (HR = 0.70). The study is also powered to evaluate a significant increase in overall survival (HR 0.67). Safety, feasibility, and quality of life endpoints critical to adjuvant therapy considerations will be evaluated. PROSPER RCC exemplifies team science with a wealth of embedded correlative work aimed at investigating the impact of the baseline immune milieu, the changes induced by neoadjuvant anti-PD-1 priming, and how both correlate with clinical outcomes. Clinical trial information: NCT03055013.
ISRAEL
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Dirk Elston, Erik Stratman, Stanley Miller, Elise Olsen, Emilia Hodak, Thomas Anderson, Joi Carter, Marsha Henderson, Kevin Cooper, Henry Lim, Iris Wieser, Won Oh, Rakhshandra Talpur, Madeleine Duvic, Vladimir Bolshinsky, Matthew Lin, Jonathan Serpell, Michael Leung, Rory Wolfe, Catriona Mclean, John Kelly, Phoebe Rich, Melinda Gooderham, Joana Goncalves, Robert Day, Rongdean Chen, Jeffrey Crowley, Andrew Patterson, Benjamin Kaffenberger, Richard Keller, Jason Reichenberg, Aaron Hauptman, Henry Robertson, Eric Finzi, Tillman Kruger, M Wollmer, Michelle Magid, Hadeel Mitwalli, Christopher Dolan, Robert Bacigalupi, Hooman Khorasani, Alexandra Zeitany, Edith Bowers, Dean Morrell, Judy Qiang, Ali Shahbaz, Whan Kim, Joseph Marinas, Simon Greaves, Jensen Yeung, Juul Van Den Reek, Philippe Pijls, Marcia Tummers, Piet Van Riel, Wietske Kievit, Frank Hoentjen, Elke De Jong, Alexander Maley, Samit Patrawala, Benjamin Stoff, Teresa Fu, Susan Swetter, Li Tao, Alan Geller, Christina Clarke, Theresa Keegan, Daniel Shaw, Michelle Maciag, Lionel Bercovitch, Justin Chia, Kara Eroglu, Dicle Orhan, Gina Montealegre-Sanchez, Adriana De Jesus, Raphaela Goldbach-Mansky, Edward Cowen, Melissa Danesh, Alexa Kimball, Andrew Bronin, Robert Phelps, Robert Sidbury, Franco Rongioletti, Laura Atzori, Caterina Ferreli, Annalisa Pinna, Natalia Aste, Monica Pau, Juliana Casagrande, Tavoloni Braga, Francisco Paschoal, Cristina Moraes, Pinto Blumetti, Maria Bussade, Joa˜o Duprat, Gilles Landman, Gisele Rezze, Aayush Gupta, Yugal Sharma, Keenan Hogan, Jarrod Cullan, Daniel Aires
Journal: Journal of the American Academy of Dermatology (2015)
Transposed Pix
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Economics
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extensive Troponin I and T Modification Detected in Serum From Patients With Acute Myocardial Infarction
Authors: Robert C. Payne, Barry I. Bluestein, David L. Morris
Journal: Circulation (2001)

A recent article in Circulation 1 characterizes the stability of human recombinant cardiac troponin I spiked into normal human serum.The authors incorrectly concluded on the basis of these studies that the accuracy of the Bayer Immuno 1 troponin I method would decrease with time after the onset of an ischemic event, increasing the risk of a false-negative diagnosis in patients with minor myocardial damage and late admittance to the emergency department.More than 90% of cardiac troponin I in serum is complexed to troponin C, and little or none is found in a free, uncomplexed form. 2,3Moreover, the apparent stability of cardiac troponin I in serum is greatly enhanced by complexation with troponin C, which is due in part to proteolytic shielding. 4Thus, the stability characteristics of free recombinant cardiac troponin I do not mimic those of the troponin I complex as it exists in patient sera and, therefore, they have little clinical relevance.In a recent study, troponin I measurements by the Bayer Immuno 1 method were performed with actual patient samples incubated at room temperature and at 4°C for up to 48 hours. 5Cardiac troponin I recoveries ranged between 96% and 105%, indicating no decline in recovery.The troponin I epitopes recognized by the antibodies used in the Bayer Immuno 1 method are contained on a proteolytic-resistant region between amino acid residues 30 and 110. 4 This accounts for the troponin I stability in samples from patients with acute myocardial infarction when measured by the Bayer Immuno I method.Given that the serial patient profiles of troponin I values closely parallel those of creatine kinase-MB (which is totally independent of the in vitro study), it is highly unlikely that the reduction of troponin I concentrations is due to "some modification of troponin I . . .(that) alters its detectability by Immuno 1." 1 An additional mechanism contributing to the time-dependent quantitative loss of immunoreactive troponin I observed by the authors when spiking recombinant troponin I in vitro may be adsorption of the free troponin I to the container surfaces.Free troponin I has a strong net positive charge, and it has been established that, without appropriate precautions, significant amounts may be lost to the surface of glass tubes. 3Troponin I-troponin C complexes are less prone to this phenomena.For this reason, manufacturers recommend that glass not be used for the long-term storage of troponin I samples.
Massachusetts' New Child Abuse and Neglect Felony Law Repeals Religious Exemption
Authors: Andrew A. Skolnick
Journal: JAMA (1994)

MASSACHUSETTS has adopted a law that makes child neglect and abuse a felony and has repealed the section of an existing law that exempts parents from prosecution for religiously motivated medical neglect of children. Joining South Dakota and Hawaii, Massachusetts is the third state since 1990 to strike religious exemption from its child abuse and neglect statutes. The remaining 47 states and the District of Columbia still have statutes that provide various degrees of legal protection to parents who withhold medical care from children for religious reasons. Many of these religious exemptions inhibit prosecution even when medical neglect results in the preventable death of a child. The effort to repeal religious exemption in Massachusetts was led by a coalition of more than 25 health, child advocacy, and civil liberty groups, including the American Academy of Pediatrics and the Massachusetts Medical Society. The new law, which was signed by Gov William
Of Books and Symbols
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NIGHT BLINDNESS
Authors: Percy Fridenberg
Journal: JAMA (1934)

<h3>To the Editor:—</h3> Dr. Holcomb's interesting communication (The Journal, March 10, p. 786) mentions the fact that night blindness was known to classical medicine and yet there was, even then, the same confusion as to designation that has persisted to the present time. As shown by his quotations, both Hippocrates and Rhazes use the term "nyctalopia" to mean poor vision at night; i. e., with lowered illumination. Dr. Holcomb himself speaks of "nyctalopia" as appearing frequently in Russia with the lenten fasts. This term is generally used at present for "owl-sight," i. e., vision in the dark, or for the vision of the dark-adapted eye. For night blindness a paraphrase is made with the term "hemeralopia," meaning (good) sight in daytime; i. e., bright light; thus the "nyctalopia" in the British Black Sea Fleet during the war in the Crimea described by John Rees, quoted as hemeralopia. The logical French
In this issue
Authors: Peter Kirkpatrick, Alexandra Flemming, Charlotte Harrison, Sarah Crunkhorn, Monica Flight, Asher Mullard, Man Tse, Mariam Faruqi, Catriona Rodwell, Lucie Wootton, Lewis Packwood, Susanne Harris, Vicky Summersby, Patrick Morgan, Kirsten Managing, Judith Shadwell, Simon Fenwick, Natalie Smith, Laura Corns, Deborah Anthony, Marketing Managers, Tim Redding, Nazly De, La Rosa, Peter Collins
Journal: Nature Reviews Drug Discovery (2012)
A Clinical Manual.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MYOCARDIAL INSUFFICIENCY
Authors: Thaddeus D. Labecki
Journal: JAMA (1949)

<h3>To the Editor:—</h3> I refer to the excellent article by Dr. George R. Herrmann on myocardial insufficiency inThe Journalof June 11. On page 509 is a statement referring to the direct application of the Fick principle: "Cardiac output equals the total oxygen consumption per minute divided by auricularventricular oxygen difference times 100." I would appreciate your clarifying whether it should not be "arteriovenous" instead of "auricular-ventricular." The routine application of the Fick principle in measuring cardiac output was always based on the difference between the oxygen contents or carbon dioxide contents in arteriovenous blood samples. It may be that the venous catheterization of the right atrium, right ventricle and pulmonary artery introduced a new method in measuring the cardiac output. Your explanation on the subject will be greatly appreciated.
Thyroiditis May Involve Lymphocytic Mutation
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Experiences with two-way television in a teaching hospital complex
Authors: J. P. Tampas
Journal: JAMA (1968)

Television has been developed and used extensively at the University of Vermont College of Medicine for consultation, patient care, teaching, and research. Present uses include televised monitoring of fluoroscopic examinations, radiographs, electrocardiograms, microscopic images, teaching conferences, operative procedures, and patients undergoing radiation therapy. Projected plans include the development of a two-way audiovisual transmission between the medical center and peripheral community hospitals for teaching and consultation purposes.
Analysis of Health Effects Resulting from Population Exposures to Acid Precipitation Precursors
Authors: Haluk Ozkaynak, John D. Spengler
Journal: Environmental Health Perspectives (1985)

Types of available studies relevant to the quantification of air pollution health effects and their principal limitations are discussed. Assessments are provided based on review and re-analysis of previously reported data bases, synthesis of published findings, and original analysis of health data sets using new methods or recent size-specific particle mass measurements. Interim results from ongoing research activities on airborne particle health effects are presented. It is shown that preliminary results obtained from cross-sectional and time-series mortality studies appear to be consistent, indicating that particulate air pollution, even at current levels, could be of concern for public health. Throughout the paper, methodological deficiencies and remaining gaps in knowledge are identified. In particular, uncertainties associated with the reported exposure-response coefficients are assessed. Finally, by characterizing the limitations of analysis we propose various recommendations for future studies and research that will serve to further define the nature, magnitude, and uncertainties of air pollution health risks.